President-elect Obama selects former Senate majority leader Tom Daschle as HHS secretary
PRESIDENT-ELECT BARACK OBAMA MOVED QUICKLY in selecting former Senate Majority Leader Tom Daschle as secretary of Health and Human Services. Daschle has been a close advisor to Obama and now will be the administration's point person on moving health reform legislation through Congress. Reform advocates consider the selection a sign that the Obama administration will seek to fulfill its promises to make health reform a top priority.
Daschle's familiarity with health policy issues is evident in the book he co-authored earlier this year: "Critical: What We Can Do About the Health-Care Crisis." With less administrative experience than the governors who preceded him, Daschle will need capable deputies to oversee key HHS agencies, including the Food and Drug Administration, the National Institutes of Health and CMS.
The former senator from South Dakota lost his seat in a hard-fought battle in 2004. He was criticized then as being too much of a Washington insider, and his nomination provoked similar comments from some parties. Most observers regard the appointment as agreement that consummate political skill is needed to reform the nation's healthcare system.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More